ESR1 and breast carcinoma: In the analysis of estrogen receptor status, LAN exposure exhibited a slightly stronger impact on breast cancer risk for cases with estrogen receptor positivity (RR = 1.10; 95% CI: 1.03–1.18; I2 = 17.0%, p = 0.005) compared to cases with estrogen receptor negativity (RR = 1.07; 95% CI: 0.94–1.21; I2 = 0.0%, p = 0.316).